FibroGen is a leading biotechnology company focused on fibrotic and cardiovascular disorders. Its lead product: Roxadusat is a revolutionary new small molecule therapy for the treatment of anemia in patients with chronic kidney disease that is expected to gain FDA approval in 2020. Roxadustat was the result of a Nobel prize winning discovery by Dr. Bill Kaelin of a new class of Prolyl 4-Hydroxylase inhibitors associated with Hypoxia (HIF-P4H) for the treatment of anemia.